☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC November Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Quetiapine fumarate (Seroquel XL®) has been accepted for use in the the treatment of schizophrenia and manic episodes associated with bipolar disorder based on similar or lower costs compared to immediate-release quetiapine.

Insulin glulisine (Apidra®) has been restricted to use in the treatment of adolescents and children, 6 years or older with diabetes mellitus, where treatment with insulin is required and for whom soluble human insulin is inappropriate. This medicine has previously accepted with the same restrictions for use in adults.

Insulin lispro (Humalog KwikPen®, Mix25 KwikPen®, Mix50 KwikPen®) have all been accepted (KwikPen, Mix 25 and 50) for the treatment of patients with diabetes mellitus who require insulin for maintenance of normal glucose homeostasis, for whom either a short-acting insulin analogue or a biphasic insulin analogue is appropriate.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC November Update' by emailShare 'SMC November Update' on FacebookShare 'SMC November Update' on TwitterShare 'SMC November Update' on LinkedInShare 'SMC November Update' on reddit


No Comments to “SMC November Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.